Overview

ERG/EOG Study in AMD Patients Treated With Ranibizumab

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label study assessing electrophysiologic testing of the retina with Electoretinogram (ERG) /Electrooculogram (EOG) tests in patients with exudative age-related macular degeneration (AMD). The standard FDA-approved treatment for wet AMD is ranibizumab (Lucentis). This study focuses on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD.
Details
Lead Sponsor:
Retina Center, Minnesota
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab